September 28, 2021
Can we beat lung cancer? OXcan, can. Every day in the UK, around 130 people are diagnosed with lung cancer. If you’re diagnosed during its earliest stage, you have a 57% chance of living for more than five years. If you’re diagnosed during its latest stage, your chances of survival are reduced to just 3%. That’s why lung cancer is the deadliest cancer anyone can face. Fortunately, OXcan is striving to identify more cases, earlier.
Read the full article
10.20.2021
Ahead of the OXFO annual Demo Day in November, they look at some of the success stories of our past-cohort ventures and how the Elevate accelerator has played a pivotal role in their growth. This snippet focuses on Oxford Cancer Analytics (OXcan), which was one of their portfolio ventures in cohort 3 in 2020.
Read more
3.15.2019
The overall winner of the £10,000 prize for the best idea in the All-Innovate contest was DECancer.AI, developed by a team from Jesus College. Their personalised diagnostic platform uses AI to detect early cancer through analysis of an affordable blood test, combined with personalised medical history of the patient, allowing early treatment and cure.
Read more
9.28.2021
Peter Jianrui Liu and Andreas Halner are the Co-founders of Oxford Cancer Analytics (OxCAN), one of the portfolio ventures on cohort 3 of the OXFO L.E.V8 accelerator at the Oxford Foundry. OxCAN offers personalised platforms to detect cancer early through a blood test to enable targeted curative treatments. Peter (Jesus College) is a DPhil candidate in Clinical Medicine, and Andreas (St John's) is doing a DPhil in Clinical Medicine and Machine Learning. In 2019, the duo won the grand prize in the Oxford Foundry's All-Innovate student ideas competition, which returns this month.
Read more
11.23.2020
KQ Labs, an accelerator programme focused on data-driven health, run by the Francis Crick Institute and now funded by LifeArc, has selected ten new start-ups for its third cohort.
Read more
For press enquiries, interviews and requests to re-use content, please contact us
